Odyssey Therapeutics ODTX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 93rd percentile, 5-year average -5.9x
Above its usual level · 73rd percentile, 5-year average 0.5x
#3433 of 5329 stocks by PB (1 = cheapest)
Around its usual level · 59th percentile, 5-year average 5,709.4x
#5138 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.45 | – | 0.51 | 73% (pricier than usual) | #3433 of 5329 (1 = cheapest) |
| PE | -5.17 | -3.90 | -5.91 | 93% (pricier than usual) | – |
| PS | 9,293.12 | – | 5,709.40 | 59% (pricier than usual) | #5138 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ODTX.
Sign in to join the discussion.